Reply to Liver‐intestine Cadherin Predicts Microvascular Invasion and Poor Prognosis of Hepatitis B Virus‐positive Hepatocellular Carcinoma

Ying‐Hong Shi,Zhen–Bin Ding,Jun Fan
DOI: https://doi.org/10.1002/cncr.25110
IF: 6.9209
2010-01-01
Cancer
Abstract:We read with great interest the article in Cancer by Ding et al. Using the RNA interference (RNAi) strategy, they performed in vitro assays and concluded that liver-intestine cadherin (LI-cadherin) was a positive regulator of the migratory, adhesive, and invasive behavior of hepatocellular carcinoma (HCC) cells. Furthermore, immunohistochemical analysis using tissue samples of hepatitis B virus (HBV)-positive HCC indicated that overexpression of cytoplasmic LI-cadherin was associated with vascular invasion and poor prognosis. LI-cadherin, a transmembrane protein with 7 tandemly repeated extracellular domains and a short cytoplasmic domain, is primarily localized at the plasma membrane. In fact, many previous studies have demonstrated positive membranous immunostaining for LI-cadherin and analyzed the correlation between such LI-cadherin expression and clinicopathological parameters and prognosis. Conversely, some studies have demonstrated that LI-cadherin is predominantly localized in the cytoplasm of diffuse-type gastric carcinoma and HCC, although these observations were not discussed in detail. In their study, Ding et al did not analyze membranous LI-cadherin expression in samples of HBV-positive HCC, and therefore it was unclear whether there was any alteration of membranous LI-cadherin expression duringHCC progression. Liu et al recently provided supportive evidence that the RNAi-mediated knockdown of LI-cadherin ameliorates the tumorigenic and malignant phenotypes of HCC cells and inactivates Wnt/b-catenin signaling (relocalization of b-catenin to the cytoplasm with a concomitant reduction in cyclin D1 and an increase in retinoblastoma), thereby inhibiting tumor growth and enhancing cell death. We believe that LI-cadherin is a useful biomarker and therapeutic target for HCC with an aggressive phenotype.
What problem does this paper attempt to address?